Guru Sonpavde

Guru Sonpavde is a bladder cancer oncologist at Dana-Farber who has made significant contributions to perioperative treatment strategies for muscle-invasive bladder cancer. His research has advanced understanding of neoadjuvant chemotherapy and the role of adjuvant immunotherapy including nivolumab after radical cystectomy. He has been a key investigator in CheckMate 274 establishing nivolumab as the first FDA-approved adjuvant therapy for high-risk muscle-invasive urothelial cancer. He maintains major databases for population-level bladder cancer research.